RxDoctor Payments Data

Thomas Lombardo, MD

Cardiovascular Disease · Beaumont, TXNPI 1891791091

Payments from drug & device makers

$12,893in general payments, 2019–2025

Across 320 payments — averaging $40.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$7K
  • Boston Scientific$1K
  • Edwards Lifesciences$1K
  • Shockwave Medical, Inc$632
  • Abbott$477
  • Actelion Pharmaceuticals US, Inc.$294
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,93346%
  • Education$1,37711%
  • Other$5,58343%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,893 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$399,442
Medicare patients
1,836
Services billed
5,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban622$585,271
XareltoRivaroxaban180$177,681
EntrestoSacubitril/Valsartan120$124,809
MultaqDronedarone Hcl52$53,278
Repatha SureclickEvolocumab58$45,535
NexlizetBempedoic Acid/Ezetimibe75$37,037
Ranolazine ErRanolazine157$17,992
Metoprolol Succinate1,000$15,294
Repatha PushtronexEvolocumab21$14,559
BrilintaTicagrelor16$7,839
ClopidogrelClopidogrel Bisulfate670$7,645
Praluent PenAlirocumab16$7,542
Amiodarone Hcl180$6,718
Isosorbide Mononitrate ErIsosorbide Mononitrate412$4,995
Nitroglycerin177$4,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$585,271622 claims
Johnson & JohnsonXarelto$179$177,681180 claims
NovartisEntresto$234$124,809120 claims
Sanofi-aventis U.S. LLCMultaq$113$53,27852 claims
Esperion Therapeutics, Inc.Nexlizet$175$37,03775 claims
AstraZenecaBrilinta$197$7,83916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →